GSK
For UK Healthcare Professionals
Articles on other parts of this website may contain promotional information

Need help to identify your ‘at risk’ respiratory patients?


  • Reading time

    3 min read

  • Rating

    6
    0
  • Your expert

    Expert Placeholder
    Simon Thomas
    Honorary Fellow of the School of Pharmacy & Bioengineering, Keele University and a Director at Prescribing Decision Support

The timely, workable and systematic identification of patients for respiratory reviews is an important part of patient care. In practice however, prioritising patients is often challenging. Setting up audits can be time consuming and requires a knowledge of GP clinical systems to ensure the accuracy and integrity of search queries and coding.

Both the National Review of Asthma Deaths and National COPD Audit Programme have identified a series of avoidable risk factors for patients living with asthma and COPD.1,2 Corresponding quality improvement recommendations that would reduce the number of preventable attacks and improve disease control have been made with many of these recommendations echoed in both national policy and guidance issued by NICE, BTS/SIGN, NHSE, MHRA, GINA and GOLD 3-12

Amongst their key findings, data from the National Review of Asthma Deaths and National COPD Audit Programme showed that:

Placeholder

What is the Asthma and COPD Audit and Review Toolkit?

To support the implementation of many of these recommendations1,2 and simplify the search and identification process - GSK sponsored the Asthma and COPD Audit and Review Toolkit. GSK was involved in scoping for the Toolkit and has reviewed the Toolkit for compliance with the ABPI Code. The toolkit was developed as part of a partnership between the Midlands Practice Pharmacy Network and Prescribing Decision Support Ltd at the Centre for Medicines Optimisation, Keele University.

The Asthma and COPD Audit and Review Toolkit is a free, downloadable resource which incorporates SNOMED CT coding and consists of eight distinct protocol alerts and a consolidated search report. All search queries and reports incorporate many of the risk factors identified by the National Review of Asthma Deaths and National COPD Audit Programme. In turn, this will help practitioners identify and prioritise both asthma and COPD patients for review who may be at risk of exacerbations, unplanned admissions and/or displaying signs of poor disease control.

Summary

The asthma and COPD audit and review toolkit can support you in proactively identifying patients who have a risk factor(s) identified by National Review of Asthma Deaths and National COPD Audit Programme and prioritise them for review. Its alert functionality will also help you to opportunistically ‘catch’ patients when they present at the surgery for other reasons, allowing you to take advantage of opportunities to enquire about their COPD or asthma and optimise patient care.


Get started with the free download* and installation guide

*Currently available for EMIS Web. SystmOne version to follow



References

1. Royal College of Physicians. Why asthma still kills: the National Review of
Asthma Deaths (NRAD) Confidential Enquiry report. 2014.

2. Royal College of Physicians. Planning for every breath. National Chronic
Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit
(Wales) 2015–17. National report. 2017.

3. NICE. Asthma: medicines safety priorities. Key therapeutic topic KTT5. Updated
March 2019.

4. NHSE. The NHS Long Term Plan. January 2019.

5. Asthma UK. Patient safety failures in asthma care: the scale of unsafe
prescribing in the UK. 2015.

6. MHRA. Asthma Long-acting ß2 agonists: use and safety. Guidance. December 2014.

7. Department of Health. Community pharmacy in 2016/17 and beyond. October 2016.

8. British Thoracic Society, Scottish Intercollegiate Guideline Network. SIGN 153
- The British Guideline on the Management of Asthma. 2016.

9. Global Initiative for Asthma. The Global Strategy for Asthma Management and
Prevention. 2017.

10. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention
(for Adults and Children Older than 5 years). 2019.

11. NICE. Chronic obstructive pulmonary disease in adults. Quality standard QS10.
February 2016.

12. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the
diagnosis, management, and prevention of chronic obstructive pulmonary disease.
2019 report.

NP-GB-RS-WCNT-200019 v2 August 2020

Rate this article

  • Reading time

    3 min read

  • Rating

    6
    0
  • Your expert

    Expert Placeholder
    Simon Thomas
    Honorary Fellow of the School of Pharmacy & Bioengineering, Keele University and a Director at Prescribing Decision Support